mouse rm-9 prostate cancer cells Search Results


rm9 cells  (ATCC)
94
ATCC rm9 cells
Figure 5. Effect of VSV-hIFNb RT in LNCaP, PC3, and <t>RM9</t> tumors. A, Male athymic nude mice (4–8 weeks old) were orthotopically implanted with LNCaP cells (n ¼ 10/group). When serum PSA level reached 3 to 8 ng/mL, VSV-hIFNb (1 101 PFU) was injected intratumorally. Tumors were irradiated with a single dose of 5 Gy 24 hours postinfection. PSA values for 10 weeks posttreatment are plotted as mean SEM. B, PC3 cells were implanted subcutaneously (3 106 cells) into the right legs (n ¼ 15/group). Intratumoral injection with VSV-hIFNb (1 105 PFU) was started when the tumors reached 50 mm3. RT at 5 Gy was given alone or 24 hours post-VSV-hIFNb infection. TVs are plotted as mean SEM. C, RM9 cells were injected subcutaneously (1 104 cells) in C57BL/6 male mouse (n ¼ 13/group). VSV-mIFNb (1 105 PFU) and/or RT treatment was initiated when the tumor size reached 50 mm3. RT was given as either 5 Gy on 1 day (1) or 5 Gy/day for 5 days (5). TVs were plotted as mean SEM. D, Representative images of mice bearing RM9 tumors infected with VSV-mIFNb followed by radiation 5 Gy 5 shown from day 1 to 30 postinfection. E, RM9 rechallenge experiments were carried out in tumor-bearing mice previously treated with VSV-mIFNb (1 105 PFU) þ RT 5 Gy 5x. On day 30 after VSV-mIFNb þ RT (day 0 for rechallenge), mice were injected with RM9 1 104 cells in the contralateral flank. Beginning at day 30 after VSV-mIFNb infection, CD8 depletion was carried out using anti-CD8 antibody (125 mg/5 days) administered intraperitoneally every third day until termination of the experiment. Control mice were administered with the IgG2b isotype-matched control antibody. All of the above rechallenged mice were monitored for survival and tumor growth for 30 more days. Mice were euthanized when tumors measured 500 mm3. TVs are plotted as mean SEM from each treatment group. For quantification of CD8 and CD4 spleen cells, splenocytes were isolated and stained with fluorescent-tagged antibodies against CD8 (F) and CD4 (G), and quantified by flow cytometry (n ¼ 6 per group). Horizontal lines indicate means of results.
Rm9 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+rm-9+prostate+cancer+cells/RM-9/10__1158_slash_1541___7786__mcr___19___0836-48-6-33
Average 94 stars, based on 1 article reviews
rm9 cells - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
rm9-psca-fluc cells  (Corning Life Sciences)
90
Corning Life Sciences rm9-psca-fluc cells
Figure 5. Effect of VSV-hIFNb RT in LNCaP, PC3, and <t>RM9</t> tumors. A, Male athymic nude mice (4–8 weeks old) were orthotopically implanted with LNCaP cells (n ¼ 10/group). When serum PSA level reached 3 to 8 ng/mL, VSV-hIFNb (1 101 PFU) was injected intratumorally. Tumors were irradiated with a single dose of 5 Gy 24 hours postinfection. PSA values for 10 weeks posttreatment are plotted as mean SEM. B, PC3 cells were implanted subcutaneously (3 106 cells) into the right legs (n ¼ 15/group). Intratumoral injection with VSV-hIFNb (1 105 PFU) was started when the tumors reached 50 mm3. RT at 5 Gy was given alone or 24 hours post-VSV-hIFNb infection. TVs are plotted as mean SEM. C, RM9 cells were injected subcutaneously (1 104 cells) in C57BL/6 male mouse (n ¼ 13/group). VSV-mIFNb (1 105 PFU) and/or RT treatment was initiated when the tumor size reached 50 mm3. RT was given as either 5 Gy on 1 day (1) or 5 Gy/day for 5 days (5). TVs were plotted as mean SEM. D, Representative images of mice bearing RM9 tumors infected with VSV-mIFNb followed by radiation 5 Gy 5 shown from day 1 to 30 postinfection. E, RM9 rechallenge experiments were carried out in tumor-bearing mice previously treated with VSV-mIFNb (1 105 PFU) þ RT 5 Gy 5x. On day 30 after VSV-mIFNb þ RT (day 0 for rechallenge), mice were injected with RM9 1 104 cells in the contralateral flank. Beginning at day 30 after VSV-mIFNb infection, CD8 depletion was carried out using anti-CD8 antibody (125 mg/5 days) administered intraperitoneally every third day until termination of the experiment. Control mice were administered with the IgG2b isotype-matched control antibody. All of the above rechallenged mice were monitored for survival and tumor growth for 30 more days. Mice were euthanized when tumors measured 500 mm3. TVs are plotted as mean SEM from each treatment group. For quantification of CD8 and CD4 spleen cells, splenocytes were isolated and stained with fluorescent-tagged antibodies against CD8 (F) and CD4 (G), and quantified by flow cytometry (n ¼ 6 per group). Horizontal lines indicate means of results.
Rm9 Psca Fluc Cells, supplied by Corning Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+rm-9+prostate+cancer+cells/rm9+psca+fluc+cells/10__1158_slash_1078___0432__ccr___18___1382-120-10-17
Average 90 stars, based on 1 article reviews
rm9-psca-fluc cells - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
du 145  (ATCC)
99
ATCC du 145
Figure 5. Effect of VSV-hIFNb RT in LNCaP, PC3, and <t>RM9</t> tumors. A, Male athymic nude mice (4–8 weeks old) were orthotopically implanted with LNCaP cells (n ¼ 10/group). When serum PSA level reached 3 to 8 ng/mL, VSV-hIFNb (1 101 PFU) was injected intratumorally. Tumors were irradiated with a single dose of 5 Gy 24 hours postinfection. PSA values for 10 weeks posttreatment are plotted as mean SEM. B, PC3 cells were implanted subcutaneously (3 106 cells) into the right legs (n ¼ 15/group). Intratumoral injection with VSV-hIFNb (1 105 PFU) was started when the tumors reached 50 mm3. RT at 5 Gy was given alone or 24 hours post-VSV-hIFNb infection. TVs are plotted as mean SEM. C, RM9 cells were injected subcutaneously (1 104 cells) in C57BL/6 male mouse (n ¼ 13/group). VSV-mIFNb (1 105 PFU) and/or RT treatment was initiated when the tumor size reached 50 mm3. RT was given as either 5 Gy on 1 day (1) or 5 Gy/day for 5 days (5). TVs were plotted as mean SEM. D, Representative images of mice bearing RM9 tumors infected with VSV-mIFNb followed by radiation 5 Gy 5 shown from day 1 to 30 postinfection. E, RM9 rechallenge experiments were carried out in tumor-bearing mice previously treated with VSV-mIFNb (1 105 PFU) þ RT 5 Gy 5x. On day 30 after VSV-mIFNb þ RT (day 0 for rechallenge), mice were injected with RM9 1 104 cells in the contralateral flank. Beginning at day 30 after VSV-mIFNb infection, CD8 depletion was carried out using anti-CD8 antibody (125 mg/5 days) administered intraperitoneally every third day until termination of the experiment. Control mice were administered with the IgG2b isotype-matched control antibody. All of the above rechallenged mice were monitored for survival and tumor growth for 30 more days. Mice were euthanized when tumors measured 500 mm3. TVs are plotted as mean SEM from each treatment group. For quantification of CD8 and CD4 spleen cells, splenocytes were isolated and stained with fluorescent-tagged antibodies against CD8 (F) and CD4 (G), and quantified by flow cytometry (n ¼ 6 per group). Horizontal lines indicate means of results.
Du 145, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+rm-9+prostate+cancer+cells/DU+145/custom%40htb-81%4030337279
Average 99 stars, based on 1 article reviews
du 145 - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
raw 264.7  (ATCC)
99
ATCC raw 264.7
Figure 5. Effect of VSV-hIFNb RT in LNCaP, PC3, and <t>RM9</t> tumors. A, Male athymic nude mice (4–8 weeks old) were orthotopically implanted with LNCaP cells (n ¼ 10/group). When serum PSA level reached 3 to 8 ng/mL, VSV-hIFNb (1 101 PFU) was injected intratumorally. Tumors were irradiated with a single dose of 5 Gy 24 hours postinfection. PSA values for 10 weeks posttreatment are plotted as mean SEM. B, PC3 cells were implanted subcutaneously (3 106 cells) into the right legs (n ¼ 15/group). Intratumoral injection with VSV-hIFNb (1 105 PFU) was started when the tumors reached 50 mm3. RT at 5 Gy was given alone or 24 hours post-VSV-hIFNb infection. TVs are plotted as mean SEM. C, RM9 cells were injected subcutaneously (1 104 cells) in C57BL/6 male mouse (n ¼ 13/group). VSV-mIFNb (1 105 PFU) and/or RT treatment was initiated when the tumor size reached 50 mm3. RT was given as either 5 Gy on 1 day (1) or 5 Gy/day for 5 days (5). TVs were plotted as mean SEM. D, Representative images of mice bearing RM9 tumors infected with VSV-mIFNb followed by radiation 5 Gy 5 shown from day 1 to 30 postinfection. E, RM9 rechallenge experiments were carried out in tumor-bearing mice previously treated with VSV-mIFNb (1 105 PFU) þ RT 5 Gy 5x. On day 30 after VSV-mIFNb þ RT (day 0 for rechallenge), mice were injected with RM9 1 104 cells in the contralateral flank. Beginning at day 30 after VSV-mIFNb infection, CD8 depletion was carried out using anti-CD8 antibody (125 mg/5 days) administered intraperitoneally every third day until termination of the experiment. Control mice were administered with the IgG2b isotype-matched control antibody. All of the above rechallenged mice were monitored for survival and tumor growth for 30 more days. Mice were euthanized when tumors measured 500 mm3. TVs are plotted as mean SEM from each treatment group. For quantification of CD8 and CD4 spleen cells, splenocytes were isolated and stained with fluorescent-tagged antibodies against CD8 (F) and CD4 (G), and quantified by flow cytometry (n ¼ 6 per group). Horizontal lines indicate means of results.
Raw 264.7, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+rm-9+prostate+cancer+cells/RAW+264%2E7/custom%40tib-71%4030337279
Average 99 stars, based on 1 article reviews
raw 264.7 - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
matrigel/pbs (1:1, v/v)  (Corning Life Sciences)
90
Corning Life Sciences matrigel/pbs (1:1, v/v)
Figure 5. Effect of VSV-hIFNb RT in LNCaP, PC3, and <t>RM9</t> tumors. A, Male athymic nude mice (4–8 weeks old) were orthotopically implanted with LNCaP cells (n ¼ 10/group). When serum PSA level reached 3 to 8 ng/mL, VSV-hIFNb (1 101 PFU) was injected intratumorally. Tumors were irradiated with a single dose of 5 Gy 24 hours postinfection. PSA values for 10 weeks posttreatment are plotted as mean SEM. B, PC3 cells were implanted subcutaneously (3 106 cells) into the right legs (n ¼ 15/group). Intratumoral injection with VSV-hIFNb (1 105 PFU) was started when the tumors reached 50 mm3. RT at 5 Gy was given alone or 24 hours post-VSV-hIFNb infection. TVs are plotted as mean SEM. C, RM9 cells were injected subcutaneously (1 104 cells) in C57BL/6 male mouse (n ¼ 13/group). VSV-mIFNb (1 105 PFU) and/or RT treatment was initiated when the tumor size reached 50 mm3. RT was given as either 5 Gy on 1 day (1) or 5 Gy/day for 5 days (5). TVs were plotted as mean SEM. D, Representative images of mice bearing RM9 tumors infected with VSV-mIFNb followed by radiation 5 Gy 5 shown from day 1 to 30 postinfection. E, RM9 rechallenge experiments were carried out in tumor-bearing mice previously treated with VSV-mIFNb (1 105 PFU) þ RT 5 Gy 5x. On day 30 after VSV-mIFNb þ RT (day 0 for rechallenge), mice were injected with RM9 1 104 cells in the contralateral flank. Beginning at day 30 after VSV-mIFNb infection, CD8 depletion was carried out using anti-CD8 antibody (125 mg/5 days) administered intraperitoneally every third day until termination of the experiment. Control mice were administered with the IgG2b isotype-matched control antibody. All of the above rechallenged mice were monitored for survival and tumor growth for 30 more days. Mice were euthanized when tumors measured 500 mm3. TVs are plotted as mean SEM from each treatment group. For quantification of CD8 and CD4 spleen cells, splenocytes were isolated and stained with fluorescent-tagged antibodies against CD8 (F) and CD4 (G), and quantified by flow cytometry (n ¼ 6 per group). Horizontal lines indicate means of results.
Matrigel/Pbs (1:1, V/V), supplied by Corning Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+rm-9+prostate+cancer+cells/pbs+matrigel++1+1+/10__1158_slash_1078___0432__ccr___18___1382-120-14-17
Average 90 stars, based on 1 article reviews
matrigel/pbs (1:1, v/v) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
celltiter 96® aqueous assay  (Promega)
90
Promega celltiter 96® aqueous assay
Figure 5. Effect of VSV-hIFNb RT in LNCaP, PC3, and <t>RM9</t> tumors. A, Male athymic nude mice (4–8 weeks old) were orthotopically implanted with LNCaP cells (n ¼ 10/group). When serum PSA level reached 3 to 8 ng/mL, VSV-hIFNb (1 101 PFU) was injected intratumorally. Tumors were irradiated with a single dose of 5 Gy 24 hours postinfection. PSA values for 10 weeks posttreatment are plotted as mean SEM. B, PC3 cells were implanted subcutaneously (3 106 cells) into the right legs (n ¼ 15/group). Intratumoral injection with VSV-hIFNb (1 105 PFU) was started when the tumors reached 50 mm3. RT at 5 Gy was given alone or 24 hours post-VSV-hIFNb infection. TVs are plotted as mean SEM. C, RM9 cells were injected subcutaneously (1 104 cells) in C57BL/6 male mouse (n ¼ 13/group). VSV-mIFNb (1 105 PFU) and/or RT treatment was initiated when the tumor size reached 50 mm3. RT was given as either 5 Gy on 1 day (1) or 5 Gy/day for 5 days (5). TVs were plotted as mean SEM. D, Representative images of mice bearing RM9 tumors infected with VSV-mIFNb followed by radiation 5 Gy 5 shown from day 1 to 30 postinfection. E, RM9 rechallenge experiments were carried out in tumor-bearing mice previously treated with VSV-mIFNb (1 105 PFU) þ RT 5 Gy 5x. On day 30 after VSV-mIFNb þ RT (day 0 for rechallenge), mice were injected with RM9 1 104 cells in the contralateral flank. Beginning at day 30 after VSV-mIFNb infection, CD8 depletion was carried out using anti-CD8 antibody (125 mg/5 days) administered intraperitoneally every third day until termination of the experiment. Control mice were administered with the IgG2b isotype-matched control antibody. All of the above rechallenged mice were monitored for survival and tumor growth for 30 more days. Mice were euthanized when tumors measured 500 mm3. TVs are plotted as mean SEM from each treatment group. For quantification of CD8 and CD4 spleen cells, splenocytes were isolated and stained with fluorescent-tagged antibodies against CD8 (F) and CD4 (G), and quantified by flow cytometry (n ¼ 6 per group). Horizontal lines indicate means of results.
Celltiter 96® Aqueous Assay, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+rm-9+prostate+cancer+cells/celltiter+glo+luminescent+cell+viability+assay/us08039606-897-280-285
Average 90 stars, based on 1 article reviews
celltiter 96® aqueous assay - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


Figure 5. Effect of VSV-hIFNb RT in LNCaP, PC3, and RM9 tumors. A, Male athymic nude mice (4–8 weeks old) were orthotopically implanted with LNCaP cells (n ¼ 10/group). When serum PSA level reached 3 to 8 ng/mL, VSV-hIFNb (1 101 PFU) was injected intratumorally. Tumors were irradiated with a single dose of 5 Gy 24 hours postinfection. PSA values for 10 weeks posttreatment are plotted as mean SEM. B, PC3 cells were implanted subcutaneously (3 106 cells) into the right legs (n ¼ 15/group). Intratumoral injection with VSV-hIFNb (1 105 PFU) was started when the tumors reached 50 mm3. RT at 5 Gy was given alone or 24 hours post-VSV-hIFNb infection. TVs are plotted as mean SEM. C, RM9 cells were injected subcutaneously (1 104 cells) in C57BL/6 male mouse (n ¼ 13/group). VSV-mIFNb (1 105 PFU) and/or RT treatment was initiated when the tumor size reached 50 mm3. RT was given as either 5 Gy on 1 day (1) or 5 Gy/day for 5 days (5). TVs were plotted as mean SEM. D, Representative images of mice bearing RM9 tumors infected with VSV-mIFNb followed by radiation 5 Gy 5 shown from day 1 to 30 postinfection. E, RM9 rechallenge experiments were carried out in tumor-bearing mice previously treated with VSV-mIFNb (1 105 PFU) þ RT 5 Gy 5x. On day 30 after VSV-mIFNb þ RT (day 0 for rechallenge), mice were injected with RM9 1 104 cells in the contralateral flank. Beginning at day 30 after VSV-mIFNb infection, CD8 depletion was carried out using anti-CD8 antibody (125 mg/5 days) administered intraperitoneally every third day until termination of the experiment. Control mice were administered with the IgG2b isotype-matched control antibody. All of the above rechallenged mice were monitored for survival and tumor growth for 30 more days. Mice were euthanized when tumors measured 500 mm3. TVs are plotted as mean SEM from each treatment group. For quantification of CD8 and CD4 spleen cells, splenocytes were isolated and stained with fluorescent-tagged antibodies against CD8 (F) and CD4 (G), and quantified by flow cytometry (n ¼ 6 per group). Horizontal lines indicate means of results.

Journal: Molecular Cancer Research

Article Title: Radiation Attenuates Prostate Tumor Antiviral Responses to Vesicular Stomatitis Virus Containing IFNβ, Resulting in Pronounced Antitumor Systemic Immune Responses

doi: 10.1158/1541-7786.mcr-19-0836

Figure Lengend Snippet: Figure 5. Effect of VSV-hIFNb RT in LNCaP, PC3, and RM9 tumors. A, Male athymic nude mice (4–8 weeks old) were orthotopically implanted with LNCaP cells (n ¼ 10/group). When serum PSA level reached 3 to 8 ng/mL, VSV-hIFNb (1 101 PFU) was injected intratumorally. Tumors were irradiated with a single dose of 5 Gy 24 hours postinfection. PSA values for 10 weeks posttreatment are plotted as mean SEM. B, PC3 cells were implanted subcutaneously (3 106 cells) into the right legs (n ¼ 15/group). Intratumoral injection with VSV-hIFNb (1 105 PFU) was started when the tumors reached 50 mm3. RT at 5 Gy was given alone or 24 hours post-VSV-hIFNb infection. TVs are plotted as mean SEM. C, RM9 cells were injected subcutaneously (1 104 cells) in C57BL/6 male mouse (n ¼ 13/group). VSV-mIFNb (1 105 PFU) and/or RT treatment was initiated when the tumor size reached 50 mm3. RT was given as either 5 Gy on 1 day (1) or 5 Gy/day for 5 days (5). TVs were plotted as mean SEM. D, Representative images of mice bearing RM9 tumors infected with VSV-mIFNb followed by radiation 5 Gy 5 shown from day 1 to 30 postinfection. E, RM9 rechallenge experiments were carried out in tumor-bearing mice previously treated with VSV-mIFNb (1 105 PFU) þ RT 5 Gy 5x. On day 30 after VSV-mIFNb þ RT (day 0 for rechallenge), mice were injected with RM9 1 104 cells in the contralateral flank. Beginning at day 30 after VSV-mIFNb infection, CD8 depletion was carried out using anti-CD8 antibody (125 mg/5 days) administered intraperitoneally every third day until termination of the experiment. Control mice were administered with the IgG2b isotype-matched control antibody. All of the above rechallenged mice were monitored for survival and tumor growth for 30 more days. Mice were euthanized when tumors measured 500 mm3. TVs are plotted as mean SEM from each treatment group. For quantification of CD8 and CD4 spleen cells, splenocytes were isolated and stained with fluorescent-tagged antibodies against CD8 (F) and CD4 (G), and quantified by flow cytometry (n ¼ 6 per group). Horizontal lines indicate means of results.

Article Snippet: LNCaP (CRL-1740, ATCC), PC3 (CRL-1435, ATCC), RM9 cells (syngeneic mouse prostate tumor cells, kindly provided by Prof. Timothy Thompson, The University of Texas MD Anderson Cancer Center, Houston, TX) and normal fibroblasts (IMR-90, ATCC) were grown in DMEMT12medium with 10% FBS, 1% L-glutamine, and 1% penicillin–streptomycin (CM-completemedium).

Techniques: Injection, Irradiation, Infection, Control, Isolation, Staining, Cytometry